Latest news : Gamida Cell Ltd.

27/25/27	Gamida Cell Ltd. cancelled the acquisition of bluebird bio, Inc. from BlackRock, Inc., The Vanguard Group, Inc. and others.	CI
22/24/22	HOOKIPA Pharma Appoints Malte Peters CEO, Terry Coelho CFO	MT
18/24/18	Gamida Cell Names Rory Nealon as Chief Financial Officer	CI
18/24/18	Gamida Cell Names Sheila Frame as Chief Commercial Officer	CI
18/24/18	Gamida Cell Ltd. Names Joe Wiley as Chief Executive Officer	CI
18/24/18	Gamida Cell Ltd. announced that it has received $30 million in funding from Highbridge Capital Management, LLC	CI
24/24/24	Gamida Cell Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
10/24/10	Gamida Cell Ltd.(NasdaqGM:GMDA) dropped from S&P Global BMI Index	CI
05/24/05	Gamida Cell Ltd.(OTCPK:GMDA.Q) dropped from NASDAQ Composite Index	CI
28/24/28	Wall Street Set to Open Flat in Thursday Trading; Q4 US GDP Revised Up, Weekly Jobless Claims Fall	MT
28/24/28	Top Premarket Decliners	MT
27/24/27	Top Midday Decliners	MT
27/24/27	Wall Street Set to Open Higher Wednesday as Investors Eye End-of-Week Economic, Inflation Data	MT

More news

Analysts' recommendations: Gamida Cell Ltd.

30/24/30	JMP Securities Downgrades Gamida Cell to Market Perform From Market Outperform	MT
15/23/15	Piper Sandler Adjusts Gamida Cell's Price Target to $2 From $5, Maintains Overweight Rating	MT
15/23/15	HC Wainwright Adjusts Price Target on Gamida Cell to $5 From $11, Keeps Buy Rating	MT
19/23/19	JMP Securities Adjusts Price Target on Gamida Cell to $6 From $8, Keeps Market Outperform Rating	MT
16/23/16	Oppenheimer Adjusts Gamida Cell Price Target to $6 From $8, Maintains Outperform Rating	MT

More recommendations

Press Releases: Gamida Cell Ltd.

27/24/27	Gamida Cell Announces Commencement of Restructuring Process Supported by Highbridge Capital Management	AQ
27/24/27	Gamida Cell Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Company Update	AQ
22/24/22	Gamida Cell to Report Fourth Quarter and Full-Year 2023 Financial Results	AQ
23/24/23	Gamida Cell Data Presented at the 2024 Tandem Meetings of ASTCT® and CIBMTR®	AQ
29/24/29	Gamida Cell Actively Pursuing Strategic Alternatives	AQ

More press releases

Managers and Directors: Gamida Cell Ltd.

Manager	Title	Age	Since
Joe Wiley CEO	Chief Executive Officer	55	-
Heayoung Shin CTO	Chief Tech/Sci/R&D Officer	-	01/06/2021
Rory Nealon COO	Chief Operating Officer	58	24/05/2024

Director	Title	Age	Since
Joe Wiley CHM	Chairman	55	-
George Hampton BRD	Director/Board Member	56	01/04/2019

More insiders

Gamida Cell Ltd is an Israel-based clinical-stage biopharmaceutical company. The Company develops cell therapies that are designed to cure cancer and rare, serious hematologic diseases. The Company is leveraging its nicotinamide (NAM)-based cell expansion technology toto expand multiple cell types including stem cells and natural killer (NK) cells while maintaining their original phenotype and potency. The Company's clinical pipeline products include: Omidubicel dedicated to hematologic malignancies and severe aplastic anemia; GDA-201 dedicated for treatment of non-Hodgkin Lymphoma; GDA-301, GDA-401, GDA-501 dedicated to treatment of solid tumors, GDA-601 dedicated to multiple myeloma.

Employees

147

Sector

Biotechnology & Medical Research

More about the company

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Delayed OTC Markets 10:24:51 24/05/2024 pm IST			5-day change	1st Jan Change
0.0170 ^USD	+2.41%		-.--%	-

Market Cap	26.18L 22.69L 21.27L 19.4L 36.5L 25Cr 37.08L 2.51Cr 97.8L 13Cr 98.3L 96.17L 42Cr	P/E 2022	-1.04x	P/E 2023	-0.72x
Enterprise Value	3.9Cr 3.38Cr 3.17Cr 2.89Cr 5.44Cr 372.28Cr 5.52Cr 37Cr 15Cr 186.36Cr 15Cr 14Cr 621.66Cr	EV / Sales 2022	-	EV / Sales 2023	5,10,81,230x
Free-Float	89.41%	Yield 2022 *	-	Yield 2023	-

3 years	0.01	1.3
5 years	0.01	5.59
10 years	0.01	15.41

Date	Insider	Type	Main position	Quantity	% Market Cap.
31/01/24	Ronit Simantov	Free	Chief Technology Officer	4,80,319	0.3621%
31/01/24	Ivan Borrello	Free	Director	2,00,000	0.1508%
31/01/24	Kenneth Moch	Free	Director	2,00,000	0.1508%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
GAMIDA CELL LTD.	+2.41%	-.--%	-.--%	-98.61%	26.19L
WUXI APPTEC CO., LTD.	+2.07%	+10.05%	+77.41%	+106.53%	7.01TCr
ARGENX SE	-0.87%	+0.08%	+36.96%	+65.04%	5.49TCr
INSMED INCORPORATED	-3.55%	-3.47%	+4.13%	+473.77%	2.89TCr
WUXI BIOLOGICS (CAYMAN) INC.	+0.04%	+12.56%	+54.67%	+5.47%	2.39TCr
BIONTECH SE	-0.97%	+1.35%	-18.05%	-13.98%	2.33TCr
PHARMAESSENTIA CORPORATION	+0.35%	+8.24%	+252.94%	+466.50%	1.84TCr
GENMAB A/S	-0.59%	+7.88%	+40.87%	-20.12%	1.88TCr
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.57%	+6.85%	+30.20%	+580.70%	1.61TCr
EXELIXIS, INC.	+1.02%	-2.66%	+32.01%	+136.22%	1.25TCr
Average	-0.06%	+7.74%	+51.11%	+170.15%	2.67TCr
Weighted average by Cap.	-0.10%	+8.03%	+55.35%	+164.08%

Gamida Cell Ltd. Share Price

Stocks

GMDA

IL0011552663

Biotechnology & Medical Research

Valuation: Gamida Cell Ltd.

Latest news : Gamida Cell Ltd.

Analysts' recommendations: Gamida Cell Ltd.

Press Releases: Gamida Cell Ltd.

Quotes and Performance

Course Extremes

Managers and Directors: Gamida Cell Ltd.

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Income Statement and Estimates

	2022	2023
Net sales	-	1.78 1.55 1.45 1.32 2.49 170.26 2.53 17.07 6.66 85.23 6.7 6.55 284.32
Net income	-7.94Cr -6.88Cr -6.45Cr -5.88Cr -11Cr -757.55Cr -11Cr -76Cr -30Cr -379.21Cr -30Cr -29Cr -1.27TCr	-6.3Cr -5.46Cr -5.12Cr -4.67Cr -8.78Cr -601.23Cr -8.92Cr -60Cr -24Cr -300.96Cr -24Cr -23Cr -1TCr
Net Debt	3.93Cr 3.41Cr 3.19Cr 2.91Cr 5.48Cr 375.15Cr 5.57Cr 38Cr 15Cr 187.79Cr 15Cr 14Cr 626.46Cr	3.64Cr 3.15Cr 2.96Cr 2.7Cr 5.07Cr 347.29Cr 5.15Cr 35Cr 14Cr 173.85Cr 14Cr 13Cr 579.94Cr